Green light from FDA - Clearance for IND and phase 2b/3 trial

Published 

November 17, 2026

September 25, 2026

AKIGAI is starting its fully financed phase 2b/3 trial in CRPS in the US in Q1_2027

AKIGAI has now a 1st generation drug! AKI-007 has received the IND clearance from the FDA.

At the same time, the FDA granted the conduct of the planned phase 2b/3 trial for that will be conducted at eight US sites.

Thank you to the entire TEAM and the investors for this extraordinary achievement!

Dear patients, we are doing this for you and the sites will be announced shortly.